GlassScriptPhysician profile
Jordan A Rees
NPI 1386007797
$2,359.22
in general payments reported to CMS, 2019-2025
26 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $213 · 2023: $535 · 2024: $642 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,146.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $321.78 | 2024-2025 | Arikayce, Brinsupri |
| Amgen INC. | $266.73 | 2022-2025 | Tezspire, Repatha, Krystexxa |
| Electromed, INC. | $206.60 | 2024-2025 | Smartvest |
| Novartis Pharmaceuticals Corporation | $180.08 | 2023-2024 | |
| Glaxosmithkline, LLC. | $164.42 | 2023-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.78 | 2023-2025 | Ofev, Jardiance, Spiriva Respimat |
| Biosense Webster, INC. | $125.17 | 2022 | |
| Verona Pharma, INC. | $119.33 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $106.59 | 2023-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $98.63 | 2023-2025 | Breztri, Tezspire |
| Edwards Lifesciences Corporation | $72.97 | 2023-2025 | Sapien 3 Ultra Resilia |
| Heartflow, INC. | $66.92 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $64.70 | 2022-2025 | |
| Lilly USA, LLC | $59.15 | 2023 | Mounjaro |
| Lexicon Pharmaceuticals, INC. | $57.60 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $49.25 | 2023-2024 | Amvuttra |
| Kestra Medical Technology Services, INC. | $34.55 | 2025 | Assure Wcd |
| Mallinckrodt Hospital Products INC. | $34.03 | 2024 | Acthar |
| Kiniksa Pharmaceuticals International, Plc | $27.89 | 2024 | Arcalyst |
| Exact Sciences Corporation | $25.95 | 2025 | Cologuard Collection Kit |
| Calliditas Therapeutics US INC. | $24.09 | 2024 | |
| Pfizer INC. | $20.13 | 2023 | |
| United Therapeutics Corporation | $20.08 | 2022 | |
| Seqirus USA INC | $19.02 | 2022 | |
| Esperion Therapeutics, INC. | $16.59 | 2025 | Nexletol |
| Idorsia Pharmaceuticals US INC | $15.19 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.